International Gynecologic Cancer Society (IGCS) 2021 Annual Global Meeting

Virtual 30 August 2021 - 02 September 2021

Lenvatinib-pembrolizumab improves OS, PFS in advanced endometrial carcinoma regardless of DNA MMR status

16 Sep 2021 by

The combination of lenvatinib and pembrolizumab improved progression-free survival (PFS) and overall survival (OS) compared with physician’s choice of treatment (TPC) among patients with advanced endometrial cancer with prior exposure to platinum-based therapy, regardless of DNA mismatch repair (MMR) status, according to results of a phase III study presented at IGCS 2021.

Lenvatinib-pembrolizumab improves OS, PFS in advanced endometrial carcinoma regardless of DNA MMR status

16 Sep 2021

Intensive follow-up does not improve survival in endometrial cancer

13 Sep 2021 by

Intensive follow-up for 5 years did not improve overall survival (OS) or relapse-free survival (RFS) in patients who have undergone surgical treatment for endometrial cancer, according to results of the TOTEM study presented at IGCS 2021.

Intensive follow-up does not improve survival in endometrial cancer

13 Sep 2021

Cemiplimab extends OS in recurrent/metastatic cervical cancer

10 Sep 2021 by

Cemiplimab appears to extend overall survival (OS) compared with investigator’s choice (IC) of chemotherapy in patients with recurrent or metastatic (R/M) cervical cancer who have progressed on first-line platinum-based chemotherapy, results of the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial showed.

Cemiplimab extends OS in recurrent/metastatic cervical cancer

10 Sep 2021